About

About Biosima BioSima, a biotech company founded in 2022 and based in Brazil, has pioneered an innovative platform for developing exosome-based biopharmaceuticals. BioSima’s products are focused on addressing unmet medical needs by conventional therapies applied in Endocrinology (Diabetes), bone reconstruction (Orthopedics and Dentistry), and Neurology (Alzheimer's disease). BioSima’s biopharmaceuticals are developed utilizing cutting-edge R&D techniques applicable for regenerative medicine, employing exosome concentrates—nanometric extracellular vesicles produced naturally by living cells and concentrated through specific patented methods. Acting as active ingredients of biopharmaceuticals, these exosomes deliver their genetic and protein cargo to target local undifferentiated cells, aiming to stimulate their proliferative and differentiation potential for healing and repairing of diseased living tissues and organs. BioSima has built a solid track record in Brazil’s biotechnology innovation landscape, achieving significant financial milestones that strengthen its scientific and technological development capacity. Since its inception, the company has stood out in highly competitive public funding programs for applied research, securing support through federal initiatives in Brazil such as FINEP and the Ministry of Science, Technology and Innovation (MCTI). A key highlight is its approval under the “INOVADOC-Brazil” FINEP program, which provides non-reimbursable grants to high-impact projects in health and sustainability. In addition to government-backed funding, BioSima has successfully attracted seed capital from private sources — including angel investors with equity-based funding mechanisms tailored to deep tech startups. This financial support has enabled the company to structure a robust program for the development of exosome-based therapeutic products. It has also driven the consolidation of BioSima’s R&D infrastructure, the development of analytical methods, and the execution of preclinical safety and efficacy studies, both in vitro and in vivo. These advancements have positioned BioSima strategically to start regulatory planning and the technical processes required for clinical trial submissions to health authorities such as ANVISA (Brazil), FDA and EMA, in compliance with international good practices in biopharmaceutical development. The company’s financial and operational achievements to date reflect not only its strong technical foundation but also its institutional readiness and business maturity to meet the complex challenges of healthcare innovation.